Table 3 Management of Women with VTE
Category | Patients | Recommendation |
|---|---|---|
Very high risk for VTE | Previous VTE on anticoagulants; VTE in current pregnancy; Antithrombin deficiency | LMW heparin (Enoxaparin) mg/kg Twice day OR heparin adjusted dose with confirmation of pregnancy |
High risk for VTE | Previuos VTE; Protein C, S deficiency plus family history of VTE;homozygote FV or prothrombin mutation; combined thrombophilia | LMW heparin (Enoxaparin) 40 mg/day until 6–12 weeks postpartum Or fixed dose heparin |
Moderate risk for VTE | Heterozygote FV or prothrombin mutation, PS deficiency, and family history VTE | Postpartum anticoagulation LMW heparin (Enoxaparin) 40 mg/day |
Relatively low risk for VTE | Heterozygote FV or prothrombin mutation; no personal or family history VTE | Monitor for additional risks for VTE |